TELCON RF PHARMACEUTICAL. Overview
Get informed when a big investor buys or sells
+ Follow-23.83%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 200230.KQ is -23.83%. That is below the sector sector average of 11.85%. Investors often review this figure alongside TELCON RF PHARMACEUTICAL.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 200230.KQ currently prints -23.83% for ROE, while the sector average sits near 11.85%. That is roughly 301.1% below the sector mean. Large gaps often invite a closer look at TELCON RF PHARMACEUTICAL.'s growth, margins, and balance sheet.
Return on Equity shows how effectively TELCON RF PHARMACEUTICAL. converts resources into returns. At -23.83%, 200230.KQ may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 200230.KQ's ROE (-23.83%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
